Thorir Einarsson Long, MD, PhD^1,2*, Sæmundur Rögnvaldsson, MD, PhD^3*, Sigrun Thorsteinsdottir, MD, PhD^3,4, Ingigerdur Sverrisdottir, MD^3,5*, Elias Eythorsson, MD, PhD^3,6*, Olafur Indridason, MD, MHS^6*, Runolfur Palsson, MD^3,6*, Thor Aspelund, PhD^3*, Brynjar Vidarsson, MD^6*, Pall T. Onundarson, MD^3,6, Bjarni Agnarsson, MD^3,6*, Margret Sigurdardottir, MD^6*, Ingunn Thorsteinsdottir, MD, PhD^6*, Isleifur Olafsson, MD, PhD^6*, Asdis Rosa Thordardottir^3*, Asbjorn Jonsson, MD^7*, Gauti Gislason, MSc^3*, Andri Olafsson^3*, Malin Hultcrantz, MD, PhD⁸, Brian GM Durie, MD⁹, Stephen J. Harding, PhD¹⁰, Thorvardur Jon Love, MD, PhD^3,6*, Ola Landgren, MD¹¹ and Sigurdur Y. Kristinsson, MD, PhD^3,6

¹Faculty of Medicine, University of Iceland, Reykjavik, AL, Iceland
²Skåne University Hospital, Lund, Sweden
³Faculty of Medicine, University of Iceland, Reykjavik, Iceland
⁴Rigshospitalet, Copenhagen, Denmark
⁵Dept. of Haematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden
⁶Landspitali, The National University Hospital of Iceland, Reykjavik, Iceland
⁷Akureyri Hospital, Akureyri, Iceland
⁸Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁹Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
¹⁰The Binding Site Inc., Birmingham, United Kingdom
¹¹Sylvester Comprehensive Cancer Center, Myeloma Division, University of Miami, Miami, FL

Xin Jiang, PhD^1*, Jianying Wang^1*, Yao-Cheng Li, PhD^1*, Alexander B Jackman^1*, Hannah Flaherty^1*, Imani Rogers^1*, Eli Muchtar, MD², Angela Dispenzieri, MD², Brian H Spencer^3*, Vaishali Sanchorawala, MD⁴, Tatiana Prokaeva, PhD^3* and Richard Labaudiniere, PhD^1*

¹Protego Biopharma, San Diego, CA
²Mayo Clinic, Rochester, MN
³Amyloidosis Center, Chobanian & Avedisian School of Medicine, Boston University School of Medicine, Boston, MA
⁴Section of Hematology and Medical Oncology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA

Jahanzaib Khwaja¹, Sriram Ravichandran^1*, Joshua Bomsztyk^2*, Oliver Charles Cohen, MBBS, BSc, FRCPath^2*, Darren Foard^2*, Ana Martinez – Naharro^2*, Lucia Venneri^2*, Marianna Fontana^2*, Philip N Hawkins^2*, Julian Gillmore^2*, Helen J Lachmann^2*, Shameem Mahmood^2*, Carol Whelan^2* and Ashutosh D. Wechalekar, MBBS, DM, FRCP, FRCPath^2,3

¹University College London Hospitals, London, United Kingdom
²Royal Free London Hospital, National Amyloid Centre, London, United Kingdom
³Clinical Haematology, Cancer Division, University College London Hospital, London, United Kingdom

Eyal Lebel^1,2*, Shlomit Kfir-Erenfeld^2*, Nathalie Asherie^2,3*, Sigal Grisariu, MD^2,4*, Batia Avni, MD^3,4*, Shlomo Elias^2,3, Miri Assayag^2,3*, Tatyana Dubnikov^2,3*, Nomi Zalcman^3,5*, Marjorie Pick^3*, Eran Zimran, MD^2,3*, Yael C. Cohen^6,7*, Irit Avivi Mazza, MD^8,9*, Cyrille Cohen^10*, Polina Stepensky^2,3* and Moshe E Gatt, MD^3,11

¹Faculty of Medicine, the Hebrew University, Jerusalem, Jerusalem, Israel
²Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Medical Center, Jerusalem, Israel
³Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
⁴Bone Marrow Transplantation & Cancer Immunotherapy Department, Hadassah-Hebrew University Medical Center and Faculty of Medicine, the Hebrew University of Jerusalem, Jerusalem, Israel
⁵Bone marrow transplant and cellular therapy department, Hadassah Medical Center, Jerusalem, Israel
⁶Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
⁷Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
⁸Hematology Division, Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
⁹Division of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
¹⁰Laboratory of Tumor Immunology and Immunotherapy, The Mina and Everard Goodman Faculty of Life Sciences,, Bar-Ilan University, Ramat Gan, Israel
¹¹Department of Hematology, Hadassah Medical Center, Jerusalem, Israel

Efstathios Kastritis, MD^1*, Monique C Minnema^2*, Meletios A. Dimopoulos, MD, PhD¹, Giampaolo Merlini, MD^3*, Foteini Theodorakakou, MD^1*, Despina Fotiou, MD, PhD^1*, Antoine Huart, MD^4*, Karim Belhadj Merzoug^5*, Elena Papachristou, MSc^6*, Kyriaki Manousou, MSc^6*, Pieter Sonneveld, MD, PhD⁷ and Giovanni Palladini, MD, PhD³

¹Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
²Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
³Amyloidosis Research and Treatment Center, University of Pavia, Pavia, Italy
⁴Department of Nephrology and Transplantation, CHU de Toulouse Rangueil, Toulouse, France
⁵Lymphoid Malignancies Unit, Henri Mondor Hospital, Créteil, France
⁶Health Data Specialists, Dublin, Ireland
⁷Erasmus MC Cancer Institute, Rotterdam, Netherlands

Jason Valent, MD¹, Michaela Liedtke, MD², Jeffrey A. Zonder, MD³, Richa Manwani^4*, Chandrasekhar Udata, PhD^5*, Juliana Ianus, PhD^5*, John Tripptree, PharmD^5*, Julia Catini, PharmD, MBA^5* and Candida Cristina Quarta^5*

¹Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
²Stanford Cancer Center, Palo Alto, CA
³Karmanos Cancer Institute, Detroit, MI
⁴AstraZeneca, Cambridge, United Kingdom
⁵Alexion, AstraZeneca Rare Disease, Boston, MA